- Ibritumomab tiuxetan
primary sources date October 2009 drugbox type mab IUPAC name image Ibritumomab tiuxetan structure.svg ... Rx only legal status routes of administration intravenous Ibritumomab tiuxetan , sold under the trade ..., extended follow up data for the ZEVALIN 90Y ibritumomab tiuxetan First line Indolent FIT study ... History Developed by the IDEC Pharmaceuticals, which is now part of Biogen Idec , ibritumomab tiuxetan ... agents Category Monoclonal antibodies Category Cancer treatments de Ibritumomab Tiuxetan it Ibritumomab tiuxetan ... . The drug uses the monoclonal mouse IgG IgG1 antibody ibritumomab pronounced as ih bri TYOO mo mab ref http body.aol.com drugs ibritumomab Ibritumomab Pronunciation ref in conjunction with the chelator tiuxetan, to which a radioactive isotope either yttrium 90 or indium 111 is added. Tiuxetan is a modified ... to qualify for ibritumomab, a patient needs to have bone marrow involvement of 25 ref http www.zevalin.com HealthCarePro indications.htm Ibritumomab Indications ref and 15 bone marrow cellularity. Since ibritumomab is known to cause cytopenia , platelet and neutrophil counts are also taken pretreatment ... HAMA . Having bulky disease does not disqualify a patient. The ibritumomab regimen takes 7 9 days, with two administrations of ibritumomab. Each dose is preceded by rituximab , in order to pre deplete B lymphocytes. ref http www.zevalin.com HealthCarePro dosingandadministration.htm Ibritumomab ... dose uses indium 111 ibritumomab for imaging. Indium 111 emits gamma radiation , which can be picked ... 90 ibritumomab as the actual treatment. Yttrium 90 emits the cell killing beta radiation . Ibritumomab tiuxetan is administered by intravenous infusion which usually lasts around 10 minutes. Only acrylic shielding is needed, not lead. Efficacy Treatment with ibritumomab showed higher response rates in clinical trial s compared to treatment with only rituximab similar to ibritumomab, but without the attached ... more details
|
- List of drugs: Y
List of drugs Y Y y Drospirenone Yasmin Yutopar yohimbic acid International Nonproprietary Name INN yttrium Y 90 clivatuzumab tetraxetan United States Adopted Name USAN Yttrium Y 90 ibritumomab tiuxetan International Nonproprietary Name INN ... more details
|
- ATC code V10
ATC codes lead V 10 Therapeutic radiopharmaceuticals anchor V10A V10A Anti inflammatory agents anchor V10AA V10AA Yttrium Yttrium 90 sup 90 sup Y compounds V10AA01 Yttrium sup 90 sup Y citrate colloid V10AA02 Yttrium sup 90 sup Y ferrihydroxide colloid V10AA03 Yttrium sup 90 sup Y silicate colloid anchor V10AX V10AX Other anti inflammatory therapeutic radiopharmaceuticals V10AX01 Phosphorus Phosphorus 32 sup 32 sup P chromicphosphate colloid V10AX02 Samarium Samarium 153 sup 153 sup Sm hydroxyapatite colloid V10AX03 Dysprosium Dysprosium 165 sup 165 sup Dy colloid V10AX04 Erbium Erbium 169 sup 169 sup Er citrate colloid V10AX05 Rhenium Rhenium 186 sup 186 sup Re sulfide colloid V10AX06 Gold Gold 198 sup 198 sup Au colloidal anchor V10B V10B Pain palliation bone seeking agent s anchor V10BX V10BX Various pain palliation radiopharmaceuticals V10BX01 Strontium Strontium 89 sup 89 sup Sr chloride V10BX02 Samarium 153Sm lexidronam Samarium sup 153 sup Sm lexidronam V10BX03 Rhenium sup 186 sup Re etidronic acid anchor V10X V10X Other therapeutic radiopharmaceuticals anchor V10XA V10XA Iodine Iodine 131 sup 131 sup I compounds V10XA01 Sodium iodide sup 131 sup I V10XA02 Iobenguane 131I Iobenguane sup 131 sup I V10XA53 Tositumomab Tositumomab iodine sup 131 sup I tositumomab anchor V10XX V10XX Various therapeutic radiopharmaceuticals V10XX01 Sodium phosphate sup 32 sup P V10XX02 Ibritumomab tiuxetan 90Y Ibritumomab tiuxetan sup 90 sup Y References Reflist Radiopharmaceuticals Category ATC codes V10 ca Codi ATC V10 hu ATC V10 Ter pi ban haszn lt radiofarmakonok ro Cod ATC V10 sv ATC kod V10 Terapeutiska radiofarmaka th ATC V10 ... more details
|
- Tositumomab
drugbox verifiedrevid 409083424 type mab image mab type mab source o target CD20 CAS number 192391 48 3 ATC prefix V10 ATC suffix XA53 ATC supplemental sequential regimen with sup 131 sup I form PubChem DrugBank BTD00085 KEGG Ref keggcite correct kegg KEGG D08622 C 6416 H 9874 N 1688 O 1987 S 44 molecular weight 143859.7 g mol bioavailability protein bound metabolism elimination half life excretion pregnancy AU A B1 B2 B3 C D X pregnancy US A B C D X pregnancy category legal AU Unscheduled S2 S4 S8 legal UK GSL P POM CD legal US OTC Rx only legal status routes of administration Tositumomab is a drug for the treatment of follicular lymphoma . It is a IgG 2a anti CD20 monoclonal antibody derived from immortalized mouse cells. Tositumomab is applied in a sequential infusion followed by iodine sup 131 sup I tositumomab , which is the same antibody covalently bound to the radionuclide iodine 131 sup 131 sup I . ref http us.gsk.com products assets us bexxar.pdf Bexxar Prescribing Information ref sup 131 sup I emits both beta radiation beta and gamma radiation and decays with a half life of 8 days. Clinical trials have established the efficacy of the tositumomab iodine sup 131 sup I tositumomab regimen in patients with relapsed or chemotherapy rituxan refractory follicular lymphoma. This drug combination is manufactured by Corixa now GlaxoSmithKline . It sells in the U.S. under the trade name Bexxar . Bexxar was developed by Dr. Mark Kaminski and Dr. Richard Wahl. There is some evidence that it may cause a smaller decrease in platelet counts than ibritumomab tiuxetan does. ref name pmid17942813 Cite journal author Jacene HA, Filice R, Kasecamp W, Wahl RL title Comparison of 90Y ibritumomab tiuxetan and 131I tositumomab in clinical practice journal J. Nucl. Med. volume 48 issue 11 pages 1767 76 year 2007 pmid 17942813 doi 10.2967 jnumed.107.043489 url http jnm.snmjournals.org cgi pmidlookup?view long&pmid 17942813 ref References Reflist http www.med.umich.edu medschool facu ... more details
|
- List of drugs: Z
List of drugs Z Z z za zabicipril International Nonproprietary Name INN zabiciprilat International Nonproprietary Name INN zabofloxacin International Nonproprietary Name INN zacopride International Nonproprietary Name INN Zaditor zafirlukast International Nonproprietary Name INN zafuleptine International Nonproprietary Name INN sparfloxacin Zagam zalcitabine International Nonproprietary Name INN zaldaride International Nonproprietary Name INN zaleplon International Nonproprietary Name INN zalospirone International Nonproprietary Name INN zalutumumab International Nonproprietary Name INN zaltidine International Nonproprietary Name INN zaltoprofen International Nonproprietary Name INN zamifenacin International Nonproprietary Name INN Zanaflex zanamivir International Nonproprietary Name INN zankiren International Nonproprietary Name INN zanolimumab United States Adopted Name USAN Zanosar Pharmacia & Upjohn Company zanoterone International Nonproprietary Name INN Zantac zapizolam International Nonproprietary Name INN zaprinast International Nonproprietary Name INN zardaverine International Nonproprietary Name INN Zarontin Zaroxolyn zatebradine International Nonproprietary Name INN zatosetron International Nonproprietary Name INN zaurategrast International Nonproprietary Name INN Zavesca Zaxopam ze Zebeta Zefazone Zegerid Zelnorm Zemplar Zemuron Daclizumab Zenapax zenarestat International Nonproprietary Name INN zeniplatin International Nonproprietary Name INN zepastine International Nonproprietary Name INN zeranol International Nonproprietary Name INN Zerit Zestoretic Zestril Zetia zetidoline International Nonproprietary Name INN Ibritumomab tiuxetan Zevalin Biogen Idec zi Ziac Ziagen GlaxoSmithKline . Redirects to abacavir . Ziba Rx zibotentan United States Adopted Name USAN zibrofusidic acid International Nonproprietary Name INN ziconotide International Nonproprietary Name INN zidapamide International Nonproprietary Name INN Zide zidometacin International Nonproprieta ... more details
|
- Radioimmunotherapy
Radioimmunotherapy RIT uses an antibody labeled with a radionuclide to deliver cytotoxic radiation to a target cell ref Milenic DE, Brady ED and Brechbiel MW. Antibody targeted radiation cancer therapy. Nature Rev Drug Discovery 2004 3 488 98. ref . In cancer therapy, an antibody with specificity for a tumor associated antigen is used to deliver a lethal dose of radiation to the tumor cells. The ability for the antibody to specifically bind to a tumor associated antigen increases the dose delivered to the tumor cells while decreasing the dose to normal tissues. By its nature, RIT requires a tumor cell to express an antigen that is unique to the neoplasm or is not accessible in normal cells. History of available agents expand list date February 2011 class wikitable Food and Drug Administration United States U.S. FDA approval Name Description 2002 ref http www.fda.gov bbs topics ANSWERS 2002 ANS01138.html Fda Approves First Radiopharmaceutical Product To Treat Non Hodgkin S Lymphoma Bot generated title ref ref Rao AV, Akabani G, Rizzieri DA. Radioimmunotherapy for Non Hodgkin s Lymphoma. Clin Med Res. 2005 Aug 3 3 157 65. ref Ibritumomab tiuxetan Zevalin monoclonal antibody anti CD20 conjugated to a molecule that chelates Yttrium 90 . 2003 ref http www.fda.gov cder biologics products tosicor062703.htm Tositumomab and Iodine I 131 Tositumomab Product Approval Information Licensing Action Bot generated title ref Tositumomab Iodine sup 131 sup I tositumomab Bexxar links a molecule containing Iodine 131 to the monoclonal antibody anti CD20 . These medications were the first agents of radioimmunotherapy, and they were approved for the treatment of refractory non Hodgkins lymphoma . This means they are used in patients whose lymphoma is refractory to conventional chemotherapy and the monoclonal antibody rituximab . Actinium Pharmaceuticals www.actiniumpharmaceuticals.com is developing a set of radioimmunotherapy drugs that rely upon an alpha particle emitting isotope e.g., ... more details
|
- Pentetic acid
ions. In ibritumomab tiuxetan , the chelator tiuxetan is a modified version of DTPA whose carbon ... more details
|
- Cancer immunotherapy
Mylotarg 2000 humanized CD33 acute myelogenous leukemia with calicheamicin Ibritumomab tiuxetan Zevalin ... the body. Ibritumomab tiuxetan Ibritumomab tiuxetan is a murine antibody chemically linked to a chelating ... chemotherapy followed by 90Y ibritumomab tiuxetan as first line treatment for patients with follicular ... dose directly to the target cell, which has been utilized in the case of the Ibritumomab tiuxetan ... more details
|
- Biogen Idec
the U.S. rights for Zevalin ibritumomab tiuxetan , another treatment for non Hodgkin s lymphoma, to Cell ... more details
|
- Bendamustine
Y ibritumomab tiuxetan . One combination for stage III IV relapsed or refractory indolent lymphoma ... more details
|
- List of oncology-related terms
incisional biopsy incomplete Freund s adjuvant indinavir ibritumomab tiuxetan indium In 111 ibritumomab tiuxetan indium In 111 pentetreotide indole 3 carbinol indolent lymphoma indometacin induction ... xerostomia XK469 XR9576 Y YM598 ibritumomab tiuxetan yttrium Y 90 ibritumomab tiuxetan yttrium ... more details
|
- Nuclear medicine physician
Y ibritumomab tiuxetan Zevalin & sup 131 sup I tositumomab Bexxar therapy of low grade non Hodgkin ... more details
|
- CD20
. 2008 ref Clinical significance CD20 is the target of the monoclonal antibodies mAb rituximab , Ibritumomab tiuxetan , and tositumomab , which are all active agents in the treatment of all B cell lymphoma ... more details
|
- Monoclonal antibody therapy
2000 humanized CD33 Acute myelogenous leukemia with calicheamicin Ibritumomab tiuxetan Zevalin 2002 ... more details
|
- GCB DLBCL
Bexxar . Anti CD20 conjugated with radionuclide iodine 131 Ibritumomab tiuxetan Zevalin . Anti ... more details
|
- Nuclear medicine
and thyroid cancer, Yttrium 90 ibritumomab tiuxetan Zevalin and Iodine 131 tositumomab Bexxar ... more details
|
- List of monoclonal antibodies
CD4 HIV infection Ibritumomab tiuxetan Zevalin mab mouse CD20 non Hodgkin s lymphoma Igovomab Indimacis ... more details
|
- Hairy cell leukemia
years duration are not uncommon. Other B cell destroying monoclonal antibodies such as Alemtuzumab , Ibritumomab tiuxetan and I 131 Tositumomab may be considered for refractory cases. Interferon alpha ... more details
|
- Yttrium
yttrium 90 is used in drugs such as Yttrium Y 90 DOTA tyr3 octreotide and Yttrium Y 90 ibritumomab tiuxetan for the treatment of various cancer s, including lymphoma , leukemia , ovarian, colorectal ... more details
|
- Waldenström's macroglobulinemia
Alethine, Dolastatin 10, Cyclophosphamide , Ibritumomab Yttrium Y 90 Ibritumomab , ABT 263, Ofatumumab ... more details
|
Encyclopedia
top
